| Cost-effectiveness analyses of genetic and genomic diagnostic tests K Payne, SP Gavan, SJ Wright, AJ Thompson Nature Reviews Genetics 19 (4), 235-246, 2018 | 107 | 2018 |
| The economic case for precision medicine SP Gavan, AJ Thompson, K Payne Expert review of precision medicine and drug development 3 (1), 1-9, 2018 | 90 | 2018 |
| Economics of stratified medicine in rheumatoid arthritis S Gavan, M Harrison, C Iglesias, A Barton, A Manca, K Payne Current rheumatology reports 16, 1-11, 2014 | 16 | 2014 |
| A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice M Jani, S Gavan, H Chinoy, WG Dixon, B Harrison, A Moran, A Barton, ... Rheumatology 55 (12), 2131-2137, 2016 | 13 | 2016 |
| Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism? LS Penner, SP Gavan, DM Ashcroft, N Peek, RA Elliott British Journal of Clinical Pharmacology 88 (11), 4789-4811, 2022 | 9 | 2022 |
| The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review NM John, SJ Wright, SP Gavan, CM Vass The European Journal of Health Economics 20, 1123-1131, 2019 | 9 | 2019 |
| Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies SP Gavan, CY Lu, K Payne Journal of personalized medicine 9 (2), 28, 2019 | 9 | 2019 |
| Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations S Gavan, I Bruce, K Payne Lupus science & medicine 7 (1), 2020 | 5 | 2020 |
| The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression Y Wang, SP Gavan, D Steinke, KL Cheung, LC Chen Health and Quality of Life Outcomes 20 (1), 1-13, 2022 | 4 | 2022 |
| Differences between online trial participants who have used statutory mental health services and those who have not: analysis of baseline data from 2 pragmatic trials of a … S Rennick-Egglestone, C Newby, C Robinson, C Yeo, F Ng, RA Elliott, ... Journal of Medical Internet Research 25, e44687, 2023 | 3 | 2023 |
| Estimating the impact of enabling NHS information systems to share patients’ medicines information digitally R Elliott, E Camacho, S Gavan, R Keers, A Chuter | 3 | 2023 |
| Development and delivery cost of digital health technologies for mental health: Application to the Narrative Experiences Online Intervention L Paterson, S Rennick-Egglestone, SP Gavan, M Slade, F Ng, ... Frontiers in Psychiatry 13, 1028156, 2022 | 3 | 2022 |
| Factors that influence rheumatologists’ anti-tumor necrosis factor alpha prescribing decisions: a qualitative study SP Gavan, G Daker-White, K Payne, A Barton BMC rheumatology 3, 1-12, 2019 | 3 | 2019 |
| Effectiveness and cost‐effectiveness of online recorded recovery narratives in improving quality of life for people with non‐psychotic mental health problems: a pragmatic … M Slade, S Rennick‐Egglestone, RA Elliott, C Newby, C Robinson, ... World Psychiatry 23 (1), 101-112, 2024 | 2 | 2024 |
| Economics and Precision Medicine K Payne, SP Gavan | 2 | 2022 |
| AB1264 Barriers against testing anti-tnf drug levels and anti-drug antibodies in routine clinical practice SP Gavan, G Daker-White, K Payne, A Barton Annals of the Rheumatic Diseases 77 (Suppl 2), 1726-1727, 2018 | 2 | 2018 |
| Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review SP Gavan, SJ Wright, F Thistlethwaite, K Payne PharmacoEconomics 41 (6), 675-692, 2023 | 1 | 2023 |
| Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer Y Wang, SP Gavan, D Steinke, KL Cheung, LC Chen Cost Effectiveness and Resource Allocation 20 (1), 1-16, 2022 | 1 | 2022 |
| Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations SP Gavan, M Jani, J Bluett, K Payne, A Barton Rheumatology Advances in Practice 4 (2), rkaa023, 2020 | 1 | 2020 |
| IDENTIFYING FACTORS WHICH INFLUENCE THE SELECTION OF ANTI-TNF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ENGLAND S Gavan, M Harrison, A Barton, K Hyrich, J Isaacs, A Morgan, AG Wilson, ... Value in Health 19 (3), A238, 2016 | 1 | 2016 |
